AB
IMDX

Amalgamated Bank’s Insight Molecular Diagnostics IMDX Stock Holding History

Amalgamated Bank’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-457
Closed -$14K – 3149
2022
Q1 		$14K Buy
+457
New +$14.6K ﹤0.01% 2896
2021
Q4 		– Sell
-576
Closed -$41K – 2172
2021
Q3 		$41K Sell
576
-49
-8% -$4.5K ﹤0.01% 2142
2021
Q2 		$72K Buy
+625
New +$61K ﹤0.01% 2139

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Amalgamated Bank's IMDX Position: Q2 2022 in Review

Amalgamated Bank sold out of Insight Molecular Diagnostics (IMDX) in Q2 2022, closing a stake of 457 shares — an estimated $14K sold.

Amalgamated Bank first reported a position in IMDX in Q2 2021 and held it in 3 quarters. The position peaked at $72K in Q2 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • Amalgamated Bank reported no remaining Insight Molecular Diagnostics position as of Q2 2022 after selling out during the quarter.
  • Amalgamated Bank sold 457 Insight Molecular Diagnostics shares in Q2 2022, an estimated $14K.
  • Amalgamated Bank first reported a position in Insight Molecular Diagnostics in Q2 2021 and held it in 3 quarters.
  • Amalgamated Bank's Insight Molecular Diagnostics position peaked at $72K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.